Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
101 stopped studies mapped to Malignant Peritoneal and Retroperitoneal Neoplasm and descendants · 91% state a reason
Over the 101 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT05080946 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early Phase 1 | suspended | Oct 18, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Study drug is expiring. Will reopen when new drug is received. | Other (stated, no rule matched) |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant…(Spencer) | Phase 1 / Phase 2 | terminated | Dec 5, 2019 | Enterome | Strategic decision | Sponsor / business decision |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in… | Phase 1 | terminated | Jan 20, 2022 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Phase 1 | terminated | Feb 1, 2023 | Masonic Cancer Center, University of Minnesota | Product withdrawn from clinical development | Other (stated, no rule matched) |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With… | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Inge Marie Svane | Slow recruitment | Enrollment / accrual |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With… | Phase 2 | terminated | Dec 2, 2022 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent… | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant… | Phase 1 / Phase 2 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | Abandoned | Other (stated, no rule matched) |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in… | Phase 2 | terminated | Oct 7, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | The trial was halted prematurely due to slow accrual. | Enrollment / accrual |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian… | Phase 1 | terminated | Jul 13, 2018 | University of Pennsylvania | This study was halted prematurely due to recruitment barriers | Enrollment / accrual |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT03891576 | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)(Newton) | Phase 2 | terminated | Mar 27, 2019 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT05999292 | Phase 1 Study of 68Ga-R8760 | Phase 1 | terminated | Aug 21, 2023 | Radionetics Oncology | Sponsor decision | Sponsor / business decision |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With… | Phase 1 / Phase 2 | terminated | Mar 2, 2022 | Pfizer | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study… | Safety / toxicity |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan… | Phase 1 | terminated | Oct 1, 2018 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who… | — | withdrawn | Oct 3, 2011 | Gynecologic Oncology Group | not stated | Not stated |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With… | Phase 1 / Phase 2 | terminated | Oct 14, 2022 | Enlivex Therapeutics RDO Ltd. | Sponsor decision | Sponsor / business decision |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | Phase 1 / Phase 2 | terminated | Mar 24, 2021 | THERAPIM PTY LTD | For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With… | N/A | terminated | Jan 26, 2018 | ECOG-ACRIN Cancer Research Group | poor accrual | Enrollment / accrual |
| NCT01099644 | Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the… | Phase 1 | terminated | Apr 7, 2010 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns | Safety / toxicity |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | Phase 2 | withdrawn | Dec 30, 2021 | David Liebner, MD | PI decision | Other (stated, no rule matched) |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT04447014 | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | — | terminated | Jun 25, 2020 | National Cancer Institute (NCI) | To avoid the duplication of resources and effort associated with the PI switching branches. | Other (stated, no rule matched) |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | Phase 2 | withdrawn | Mar 31, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | withdrawn by PI | Other (stated, no rule matched) |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | N/A | withdrawn | Apr 29, 2020 | Dana-Farber Cancer Institute | The anomaly detection system is still under development and is not ready to test. | Other (stated, no rule matched) |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and… | Phase 2 | terminated | Dec 28, 2007 | University of Oklahoma | Study completed per investigator. | Investigator |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC… | Phase 1 | terminated | Jun 30, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawal of sponsor support | Other (stated, no rule matched) |
| NCT03312114 | Anti-PD-L1 and SAbR for Ovarian Cancer | Phase 2 | terminated | Oct 17, 2017 | University of Texas Southwestern Medical Center | low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials